Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Sangamo Therapeutics (SGMO) Accumulated Depreciation & Amortization (2016 - 2025)

Sangamo Therapeutics has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $4.0 million for Q4 2025, down 21.68% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (down 21.68% YoY), and the annual figure for FY2025 was $4.0 million, down 21.68%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $4.0 million at Sangamo Therapeutics, down from $5.1 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for SGMO hit a ceiling of $15.1 million in Q4 2023 and a floor of $4.0 million in Q4 2025.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $9.4 million (2021), compared with a mean of $9.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 65.6% in 2021 and later tumbled 66.18% in 2024.
  • Sangamo Therapeutics' Accumulated Depreciation & Amortization stood at $9.4 million in 2021, then rose by 28.28% to $12.1 million in 2022, then grew by 24.71% to $15.1 million in 2023, then tumbled by 66.18% to $5.1 million in 2024, then decreased by 21.68% to $4.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $4.0 million (Q4 2025), $5.1 million (Q4 2024), and $15.1 million (Q4 2023) per Business Quant data.